Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 14Recruiting 4Active not recruiting 4Unknown 2Withdrawn 1Terminated 1No longer available 1Available 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 8Primary Myelofibrosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Thrombocythemia, Essential 4Recurrence 4Polycythemia Vera 4Multiple Myeloma 4Lymphoma, T-Cell 4Leukemia 4Lymphoma, T-Cell, Cutaneous 3Graft vs Host Disease 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Large Granular Lymphocytic 2Hematologic Neoplasms 2Triple Negative Breast Neoplasms 1Targeted Therapy 1Prostatic Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

ruxolitinib 4Specimen Handling 2Hydroxyurea 2Biopsy 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2talazoparib 1piperine 1givinostat hydrochloride 1givinostat 1fludarabine phosphate 1fludarabine 1fedratinib 1demethoxycurcumin 1bomedemstat 1X-Rays 1Whole-Body Irradiation 1Watchful Waiting 1Tacrolimus 1Stem Cell Transplantation 1Positron-Emission Tomography 1N(4)-oleylcytosine arabinoside 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Interferons 1Interferon-alpha 1Injections 1Hematopoietic Stem Cell Transplantation 1Decitabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Polycythemia Vera × ruxolitinib × Clear all
NCT04116502 2026-04-28

MITHRIDATE

University of Birmingham

Phase 3 Recruiting
586 enrolled
Myeloid

Polycythemia Vera

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04644211 2026-01-08

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Massachusetts General Hospital

Phase 2 Recruiting
60 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT05870475 2024-07-03

PV

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
94 enrolled
Myeloid

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡